Navigation Links
Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Date:9/13/2011

SAN DIEGO, Sept. 13, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million milestone payment from Abbott to the Company.

"We are pleased that our collaboration has reached this important milestone with elagolix now being evaluated in a clinical setting for use in treating uterine fibroids," said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "This is evidence of the clinical momentum for elagolix which is moving forward in endometriosis and now uterine fibroids.  We look forward to a continued successful collaboration with Abbott."

Uterine fibroids are benign tumors that form in the wall of the uterus. They are the most common type of growth found in a woman's pelvis and are most common in women aged 30–50 years.  While many women do not have symptoms, depending on the size, location and number, uterine fibroids can cause heavy menstrual bleeding, can put pressure on the bladder and rectum, and can cause pain and nausea. Symptoms can also include miscarriage and infertility.  Depending on the symptoms, treatment sometimes requires surgery, including the total removal of the uterus.  

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.  Neurocrine Bioscience
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
3. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
4. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
5. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
6. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
7. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
8. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
10. Neurocrine Biosciences Reports Third Quarter 2010 Results
11. Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  Janssen R&D Ireland (Janssen) today ... global Phase 3 PROMISE study demonstrating that use ... to sustained virologic response 12 weeks after the ... treatment-experienced genotype 1 chronic hepatitis C adult patients ... liver fibrosis, when administered once daily with pegylated ...
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... Va. , May 21, 2013   ... 22,000 pharmacies nationwide, announces today the publication of ... America,s Post-Reform Health Care System. The white paper ... reducing costs, and seeks public engagement to avert ... Personalized Pharmacist Care refers to a range of ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3
... Health Company (NASDAQ-CM: FHCO) today announced that its exclusive ... successful in a public tender to supply the Brazilian ... FC2 Female Condoms.  The contract is valid through March ... at the Ministry of Health,s discretion. O.B. ...
... (NYSE: VAR ) is highlighting its ProBeam™ ... the 2011 PTCOG meeting here from May 8th-14th . ... frontier in proton therapy and has the potential to improve ... conventional X-ray radiotherapy," says Moataz Karmalawy, head of Varian,s particle ...
Cached Medicine Technology:The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3Varian Medical Systems Spotlights Fully Integrated Intensity Modulated Proton Therapy at PTCOG 2011 Meeting 2Varian Medical Systems Spotlights Fully Integrated Intensity Modulated Proton Therapy at PTCOG 2011 Meeting 3
(Date:5/21/2013)... Healthcare industry leaders, health information technology ... Me Up” Emerging Healthcare Technology Conference, June 10 at ... This new event is part of the 11th ... healthcare leaders being held June 10-12 at the Fluno ... , Funding for healthcare information technology (IT) grew dramatically ...
(Date:5/21/2013)... It’s nearly summer and millions of kids ... practice for summer or fall sports. In many cases ... can begin. , To help parents during this busy ... sports or camp physicals at just $29. As ... child’s medical history, perform a physical exam and complete required ...
(Date:5/21/2013)... Everspark Interactive, one of the city's leading ... over the past year – and announced another milestone ... marketing efforts for Kids II, a designer of innovative ... a local effort, specializing in search engine optimization (SEO) ... company's website. The company now offers a host of ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Tools4ever, ... solutions, has made its Self Service Reset Password Management ... SSRPM, employees can now use the service on mobile ... that end users can easily reset their Windows passwords ... set of questions correctly, the user may then reset ...
(Date:5/21/2013)... -- Racial disparities exist in the treatment of non-small ... according to a large new study. Although most ... their initial treatment, researchers found that blacks were less ... the early stages of the disease. Hispanics were more ... 2 disease than white patients. "In our study ...
Breaking Medicine News(10 mins):Health News:“Start Me Up" Healthcare Conference: Where Healthcare CIOs, Entrepreneurs and Investors Meet 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Everspark Named Interactive Marketing Company for Kids II 2Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... French . , Montreal, December 3rd, 2008 ... Dr. Robert Koenekoop from the Research Institute at the Montreal ... million from the Canadian Institutes of Health Research (CIHR) and ... fund an ambitious research project to develop innovative gene therapies ...
... instability in people with the blood disorder Fanconi anemia ... carcinomas linked to human papillomavirus (HPV), according to a ... . , Researchers led by Cincinnati Children,s Hospital Medical ... for the FA (Fanconi Anemia) gene complex triggers cellular ...
... Corporation (Nasdaq: HLTH ) announced today the final ... of its common stock at a price of $8.80 per share, ... 25, 2008. As previously announced, HLTH exercised its right to ... tender offer and has accepted for purchase 83,699,922 shares, including all ...
... Coalition for Pulmonary Fibrosis (CPF) today announced the launch of ... fighting pulmonary fibrosis (PF), a devastating and ultimately fatal disorder ... than 128,000 Americans. Prevalence and incidence of PF has ... 40,000 lives each year - the same number as breast ...
... in broccoli and cabbage works by lowering the activity ... according to a University of California, Berkeley, study appearing ... journal Proceedings of the National Academy of Sciences ... trials in humans because it was found to stop ...
... RICHMOND, Va., Dec. 3 Pernessa Seele,Founder/CEO of The Balm ... Kay and approximately 300 faith and community leaders at a,Civic ... recognizing,President George W. Bush and First Lady Laura Bush,s leadership ... It was in his first State of the ...
Cached Medicine News:Health News:CA$2.4 million toward gene therapy for human degenerative retinal diseases 2Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 2Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 3Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 4Health News:HLTH Corporation Announces Final Results of Its Tender Offer 2Health News:HLTH Corporation Announces Final Results of Its Tender Offer 3Health News:CPF Updates Patient Education Materials to Meet Growing Demand for Pulmonary Fibrosis Information 2Health News:CPF Updates Patient Education Materials to Meet Growing Demand for Pulmonary Fibrosis Information 3Health News:CPF Updates Patient Education Materials to Meet Growing Demand for Pulmonary Fibrosis Information 4Health News:Broccoli compound targets key enzyme in late-stage cancer 2Health News:Broccoli compound targets key enzyme in late-stage cancer 3Health News:The Balm In Gilead Joins Saddleback Church in Thanking President Bush for His Leadership on Addressing HIV and AIDS Around the World 2
Wire lid retractor may be clamped to surgical drape with suture or elastic band. Large pair....
Sharp. 4 mm wide. Hand-Held...
Rigid rake retractor, 3 blunt prongs....
Rees bayonet forceps, standard, 5-1/2", TC....
Medicine Products: